Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales - InnoCan Pharma (OTC:INNPF)
Innocan Pharma Corporation (CSE: INNO)(FSE: IP4) (OTC: INNPF), a pharmaceutical technology firm specializing in innovative drug delivery platforms,
Source: benzinga.com